Core Points - NCS Multistage Holdings, Inc. will present at the Sidoti Year End Virtual Conference on December 10, 2025 [1] - The company will also host virtual one-on-one meetings with investors on December 10-11, 2025 [2] - NCS is a leading provider of engineered products and support services for oil and natural gas well construction and completions [3] Company Overview - NCS provides products and services primarily to exploration and production companies for onshore and offshore wells [3] - The company's offerings are utilized in both unconventional and conventional oil and natural gas formations [3] - NCS operates in various markets, including North America, the North Sea, the Middle East, Argentina, and China [3] - NCS's common stock is traded on the Nasdaq Capital Market under the symbol "NCSM" [3]

Core Viewpoint - Pyxis Tankers Inc. reported a significant decline in revenues and net income for the third quarter of 2025 compared to the same period in 2024, primarily due to weaker charter rates in both the product tanker and dry-bulk sectors [2][3][12]. Financial Performance - For the three months ended September 30, 2025, net revenues were $9.7 million, a decrease of 29.7% from $13.8 million in the same period of 2024 [12]. - Net income attributable to common shareholders was $1.2 million, down from $3.6 million in Q3 2024, resulting in a net income per common share of $0.11 compared to $0.34 in the prior year [12][40]. - Adjusted EBITDA for Q3 2025 was $4.2 million, a decrease of $2.5 million from $6.7 million in Q3 2024 [2][12]. Market Conditions - The product tanker sector experienced a decline in time charter equivalent (TCE) revenues, which were $8.9 million, down $2.7 million or 23.5% from the comparable period in 2024 [2][3]. - The average TCE rate for MR tankers was $21,085 per day, which is 29% lower than the same period last year [4][12]. - In the dry-bulk market, the average daily TCE rate was $13,513, a slight decrease of 2.4% compared to Q3 2024, but an increase of about $700 per day from the second quarter of 2025 [5][12]. Operational Insights - As of November 20, 2025, 93% of MR available days were booked for Q4 2025 at an estimated TCE of $20,700 per day [4]. - The dry-bulk fleet's average daily TCE rate improved to $17,150 per day, with 78% of available days booked for Q4 2025 [5]. Future Outlook - The company anticipates a firm chartering environment for both product tankers and dry-bulk carriers, with modest growth in global demand for seaborne cargoes expected through 2026 [6]. - The International Monetary Fund revised its global growth forecast to approximately 3.1% through 2026, which is expected to correlate with demand growth for refined petroleum products and dry-bulk commodities [7]. - The company plans to maintain a disciplined approach to operational and financial management while seeking growth opportunities in expanding its fleet of eco-efficient vessels [9][10]. Shareholder Actions - The Board of Directors has authorized a new common stock repurchase program of up to $3.0 million through open-market transactions for a period of up to one year, reflecting the belief that the current share price does not reflect the company's value proposition [10].

Core Insights - Alpha Tau Medical Ltd. is advancing its innovative alpha-radiation cancer therapy, Alpha DaRT, with ongoing patient treatments in a U.S. multi-center pilot study for pancreatic cancer [2][5] - The company has received a radioactive material license for its New Hampshire facility, which is a significant step towards commercial readiness [2][5] - Alpha Tau has a strong financial position with a cash balance of $75.9 million, allowing for continued clinical advancement and commercial preparation [2][11] Recent Corporate Highlights - The company reported a significant increase in patient treatment rates and interest from industry peers during the third quarter of 2025 [2] - Alpha Tau has invested nearly $2 million into its New Hampshire facility in Q3 2025 to prepare for operational readiness [2] - The first patient was treated in the U.S. multi-center pancreatic cancer clinical trial, which aims to enroll up to 30 patients [5] Expected Upcoming Milestone Targets - Completion of patient recruitment in the U.S. pivotal ReSTART trial for recurrent cutaneous squamous cell carcinoma is expected by Q1 2026 [5] - The company anticipates a response from Japan's PMDA regarding marketing authorization for Alpha DaRT in treating recurrent head and neck cancer by the end of 2025 [5] - The first patient in the U.S. GBM pilot study is expected to be treated in Q4 2025 [5] Financial Results - Research and Development expenses for the nine months ended September 30, 2025, were $22.5 million, an increase from $19.5 million in the same period in 2024 [6] - Marketing expenses decreased to $1.4 million in 2025 from $1.7 million in 2024 [7] - General and Administrative expenses rose to $5.8 million in 2025 from $4.6 million in 2024 [8] - The company reported a net loss of $30.5 million, or $0.39 per share, for the nine months ended September 30, 2025, compared to a net loss of $22.3 million, or $0.32 per share, in the same period in 2024 [10][20] Balance Sheet Highlights - As of September 30, 2025, the company had cash and cash equivalents totaling $75.9 million, an increase from $62.9 million at the end of 2024 [11] - Total assets were reported at $86.2 million as of September 30, 2025, compared to $104.7 million at the end of 2024 [16][18]

Core Points - Unity Bancorp, Inc. has declared a cash dividend of $0.15 per common share, payable on December 19, 2025, to shareholders of record as of December 5, 2025 [1] - The company is headquartered in Clinton, New Jersey, with approximately $2.9 billion in assets and $2.3 billion in deposits [2] Company Overview - Unity Bank, a wholly owned subsidiary of Unity Bancorp, provides financial services to retail, corporate, and small business customers through a branch network in New Jersey and Pennsylvania [2] - The branch network covers counties including Bergen, Hunterdon, Middlesex, Morris, Ocean, Somerset, Union, and Warren in New Jersey, as well as Northampton County in Pennsylvania [2]

Core Viewpoint - Epsilon Energy Ltd. has completed the acquisition of Peak BLM Lease LLC and issued common shares as part of the transaction [1][2]. Group 1: Acquisition Details - The acquisition of Peak BLM Lease LLC closed on November 14, 2025, and was executed under a membership interest purchase agreement [1][2]. - Epsilon will issue up to 2,500,000 common shares if certain regulatory thresholds are met by the Resolution Date, which the board has determined has occurred [2]. - Following purchase price adjustments, Epsilon issued 2,234,847 common shares to Yorktown Energy Partners XI, LP, with no further consideration due under the Purchase Agreement [3]. Group 2: Company Overview - Epsilon Energy Ltd. operates as a North American onshore natural gas and oil production and gathering company, with assets located in the Marcellus, Powder River, Permian, WCSB, and Anadarko basins [4].

Core Insights - RxSight, Inc. is an ophthalmic medical device company focused on providing customized vision solutions for patients post-cataract surgery [3] - The company will participate in the Piper Sandler 37th Annual Healthcare Conference in New York City on December 3, 2025 [1][2] Company Overview - RxSight offers the RxSight Light Adjustable Lens system, which includes the Light Adjustable Lens (LAL/LAL+), Light Delivery Device (LDD™), and accessories, representing the first adjustable intraocular lens technology available commercially [3] - This technology allows for post-surgery adjustments, enabling healthcare providers to tailor vision outcomes for patients [3] Event Participation - Management is scheduled to present at the conference on December 3, 2025, at 12:00 p.m. Eastern Time, with a live and archived webcast available for investors [2]

Core Insights - CapsoVision, Inc. is participating in the Benchmark 14th Annual Discovery One-on-One Investor Conference on December 4, 2025, in New York City, with key executives attending [1][2] Company Overview - CapsoVision is a commercial-stage medical technology company focused on advanced imaging and AI-enabled solutions for gastrointestinal disease detection and diagnosis [3] - The flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that provides high-resolution visualization of the small bowel and supports cloud-based or direct video retrieval [3] - The upcoming product, CapsoCam Colon™, features enhanced AI for non-invasive colon imaging and polyp detection, with plans to expand across multiple gastrointestinal indications [3]

Core Viewpoint - PROCEPT BioRobotics is focused on advancing patient care in urology through innovative robotic solutions, particularly in the treatment of benign prostatic hyperplasia (BPH) [3]. Company Overview - PROCEPT BioRobotics manufactures the AQUABEAM and HYDROS Robotic Systems, with the HYDROS system being the only AI-powered technology delivering Aquablation therapy [3]. - The company aims to revolutionize BPH treatment globally in partnership with urologists, emphasizing the delivery of effective, safe, and durable outcomes for men suffering from lower urinary tract symptoms (LUTS) due to BPH [3]. - BPH affects approximately 40 million men in the United States, highlighting the significant market potential for the company's solutions [3]. - The company has developed a substantial body of clinical evidence, with over 150 peer-reviewed publications supporting the benefits and clinical advantages of Aquablation therapy [3]. Upcoming Events - Management will present at the 37th Annual Piper Sandler Healthcare Conference in New York City on December 2 at 8:30 a.m. Eastern Time [1]. - A live webcast of the event will be available on the company's website, with recordings archived for at least 90 days [2].

Core Insights - Toll Brothers, Inc. has launched a new luxury home community named Venado Valley in Carson City, Nevada, which is now over 50% sold [1][4] - The community offers single-story homes with various floor plans and is designed to provide a tranquil living environment with mountain views [2][4] Company Overview - Toll Brothers is recognized as the nation's leading builder of luxury homes and operates in over 60 markets across 24 states [7] - The company has been publicly traded since 1986 and is listed on the New York Stock Exchange under the symbol "TOL" [7] Community Features - Venado Valley features single-family homes ranging from 2,129 to over 2,337 square feet, with options for 3 to 4 bedrooms and 2.5 to 3.5 baths [2] - Homes are priced from the upper $600,000s and include modern architectural styles such as craftsman and ranch designs [2][4] Sales and Marketing - The community includes both built-to-order and move-in ready homes, catering to various buyer timelines [4] - The Toll Brothers Design Studio offers customers a chance to personalize their homes with a wide selection of fixtures and finishes [5] Customer Experience - The community is positioned as a convenient location with access to shops, restaurants, and outdoor recreation, enhancing the appeal for potential buyers [4]

Core Insights - Virtu Financial received recognition in seven categories at the 2025 TRADE Awards held in New York and London, highlighting its strong performance in the financial services sector [1][2]. Awards and Recognition - The company was awarded TCA Provider of the Year and Best Dark Pool Capabilities in London, and Best Customer Support & Consulting in New York [2]. - Virtu Triton, the company's multi-asset execution management system, was recognized for Best Market Access and Best Provider for both UK & Europe and North America [2]. Company Commitment and Leadership - Keith Casuccio, Global Head of Virtu Execution Services, emphasized the company's commitment to high-quality execution technology and client service globally, attributing the recognition to the hard work of the Algos, Analytics, and Triton teams [3]. Company Overview - Virtu Financial is a leading financial services firm that utilizes advanced technology to provide execution services, data, analytics, and connectivity products, delivering liquidity to global markets [4]. - The firm offers a comprehensive product suite that includes execution, liquidity sourcing, analytics, and broker-neutral, multi-dealer platforms, enabling clients to trade across hundreds of venues in over 50 countries and multiple asset classes [4].